Diosgenin Targets CaMKK2 to Alleviate Type II Diabetic Nephropathy through Improving Autophagy, Mitophagy and Mitochondrial Dynamics
Nutrients · 11.08.2023 · 15 (16) · 3554
DOI: 10.3390/nu15163554 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, online erschienen am 11.08.2023. Verfasst von Yujie Zhong und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Food Science and Engineering, Northwest A&F University, Yangling 712100, China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diosgenin, Diabetes Mellitus. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Science and Technology Plan Project of Shaanxi Province, Student's Platform for Innovation and Entrepreneurship Training Program, Student’s Platform for Innovation and Entrepreneurship Training Program.
Abstract (Originalsprache)
Diabetic nephropathy (DN) is a worldwide health problem with increasing incidence. Diosgenin (DIO) is a natural active ingredient extracted from Chinese yams (Rhizoma dioscoreae) with potential antioxidant, anti-inflammatory, and antidiabetic effects. However, the protective effect of DIO on DN is still unclear. The present study explored the mitigating effects and underlying mechanisms of DIO on DN in vivo and in vitro. In the current study, the DN rats were induced by a high-fat diet and streptozotocin and then treated with DIO and metformin (Mef, a positive control) for 8 weeks. The high-glucose (HG)-induced HK-2 cells were treated with DIO for 24 h. The results showed that DIO decreased blood glucose, biomarkers of renal damage, and renal pathological changes with an effect comparable to that of Mef, indicating that DIO is potential active substance to relieve DN. Thus, the protective mechanism of DIO on DN was further explored. Mechanistically, DIO improved autophagy and mitophagy via the regulation of the AMPK-mTOR and PINK1-MFN2-Parkin pathways, respectively. Knockdown of CaMKK2 abolished AMPK-mTOR and PINK1-MFN2-Parkin pathways-mediated autophagy and mitophagy. Mitophagy and mitochondrial dynamics are closely linked physiological processes. DIO also improved mitochondrial dynamics through inhibiting fission-associated proteins (DRP1 and p-DRP1) and increasing fusion proteins (MFN1/2 and OPA1). The effects were abolished by CaMKK2 and PINK1 knockdown. In conclusion, DIO ameliorated DN by enhancing autophagy and mitophagy and by improving mitochondrial dynamics in a CaMKK2-dependent manner. PINK1 and MFN2 are proteins that concurrently regulated mitophagy and mitochondrial dynamics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Food Science and Engineering, Northwest A&F University, Yangling 712100, China.
- Faculty of Food Science and Engineering, Kunming University of Science and Technology, Kunming 650500, China.
Förderung
- the Science and Technology Plan Project of Shaanxi Province
- Student's Platform for Innovation and Entrepreneurship Training Program
- Student’s Platform for Innovation and Entrepreneurship Training Program
Zitieren
APA
Zhong, Y., Jin, R., Luo, R., Liu, J., Ren, L., Zhang, Y., Shan, Z., & Peng, X. (2023). Diosgenin Targets CaMKK2 to Alleviate Type II Diabetic Nephropathy through Improving Autophagy, Mitophagy and Mitochondrial Dynamics. Nutrients, 15(16), 3554. https://doi.org/10.3390/nu15163554
Vancouver
Zhong Y, Jin R, Luo R, Liu J, Ren L, Zhang Y, et al. Diosgenin Targets CaMKK2 to Alleviate Type II Diabetic Nephropathy through Improving Autophagy, Mitophagy and Mitochondrial Dynamics. Nutrients. 2023;15(16):3554. doi:10.3390/nu15163554
BibTeX
@article{Zhong2023,
author = {Zhong, Yujie and Jin, Ruyi and Luo, Ruilin and Liu, Jiayu and Ren, Luting and Zhang, Yinghan and Shan, Zhongguo and Peng, Xiaoli},
title = {Diosgenin Targets CaMKK2 to Alleviate Type II Diabetic Nephropathy through Improving Autophagy, Mitophagy and Mitochondrial Dynamics},
journal = {Nutrients},
year = {2023},
volume = {15},
number = {16},
pages = {3554},
doi = {10.3390/nu15163554}
}
EUVIMED